People · Operator
Named in public records as an officer, director or promoter · active 2016–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Revitope Oncology, Inc. | — | Biotechnology | Series A | $13.4M | $296.4M | 2016 |
| C-Reveal Therapeutics Llc | — | Biotechnology | Seed | $3.3M | $111.4M | 2020 |
Mark Cobbold at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Cobbold on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Keith Flaherty | 1 | 5 |
| Andrew Allen | 1 | 4 |
| Julie Cherrington | 1 | 2 |
| Raj Mehta | 1 | 2 |
| Peter Joost | 1 | 1 |
| Cyril Benes | 1 | 1 |
| Thomas Haag | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.